Former US FDA CDER Director Says He Played Key Role In Stealth’s Elamipretide Approval

 
• By Sarah Karlin-Smith
  
Back view of businessman standing in abstract key opening in wall with bright light.
Former CDER Director George Tidmarsh said he reviewed clinical data and guided the review division during the elamipretide review. (Shutterstock)

More from Drug Review Profiles

More from US FDA